Moderna closed up about 14.4% on Tuesday at $158.83.
The driver: fresh analyst upgrades stacking on the positive Phase 3 INTerpath-001 readout from Aug 19 - the personalized mRNA cancer vaccine Moderna runs with Merck, in melanoma.
The trial data is the part actually worth understanding here, not the one-day move.
→ Why it moved: https://marketchacha.com/movers
This article is for educational and informational purposes only. It is not financial advice, investment recommendation, or a solicitation to buy or sell securities. Investing involves significant risks. I am not a SEBI-registered investment advisor. Readers should consult their own financial advisor and conduct their own research before making any investment decisions.
Comments
Join the conversation
Sign in to join the conversation.
Follow replies, add your view, and take part in the discussion.
Sign in to commentLoading comments...